JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web browser. It makes web pages functional for specific purposes and if disabled for some reason, the content or the functionality of the web page can be limited or unavailable.

Sunday, March 16, 2025

Omicron amps up concerns about long COVID and its causes

by

1139 days ago
20220131
Nancy Rose, center in mirror, speaks with her mother, Amy Russell, right, who both contracted COVID-19 in 2021, in their dining room surrounded by pictures of relatives and family, Tuesday, Jan. 25, 2022, in Port Jefferson, N.Y. More than a third of COVID-19 survivors by some estimates develop lingering problems. (AP Photo/John Minchillo)

Nancy Rose, center in mirror, speaks with her mother, Amy Russell, right, who both contracted COVID-19 in 2021, in their dining room surrounded by pictures of relatives and family, Tuesday, Jan. 25, 2022, in Port Jefferson, N.Y. More than a third of COVID-19 survivors by some estimates develop lingering problems. (AP Photo/John Minchillo)

By LAU­RA UN­GAR and LIND­SEY TAN­NER-As­so­ci­at­ed Press

 

More than a year af­ter a bout with COVID-19, Re­bekah Hogan still suf­fers from se­vere brain fog, pain and fa­tigue that leave her un­able to do her nurs­ing job or han­dle house­hold ac­tiv­i­ties.

Long COVID has her ques­tion­ing her worth as a wife and moth­er.

“Is this per­ma­nent? Is this the new norm?” said the 41-year-old Lath­am, New York, woman, whose three chil­dren and hus­band al­so have signs of the con­di­tion. “I want my life back.’’

More than a third of COVID-19 sur­vivors by some es­ti­mates will de­vel­op such lin­ger­ing prob­lems. Now, with omi­cron sweep­ing across the globe, sci­en­tists are rac­ing to pin­point the cause of the be­dev­il­ing con­di­tion and find treat­ments be­fore a po­ten­tial ex­plo­sion in long COVID cas­es.

Could it be an au­toim­mune dis­or­der? That could help ex­plain why long COVID-19 dis­pro­por­tion­ate­ly af­fects women, who are more like­ly than men to de­vel­op au­toim­mune dis­eases. Could mi­cro­clots be the cause of symp­toms rang­ing from mem­o­ry laps­es to dis­col­ored toes? That could make sense, since ab­nor­mal blood clot­ting can oc­cur in COVID-19.

As these the­o­ries and oth­ers are test­ed, there is fresh ev­i­dence that vac­ci­na­tion may re­duce the chances of de­vel­op­ing long COVID.

It’s too soon to know whether peo­ple in­fect­ed with the high­ly con­ta­gious omi­cron vari­ant will de­vel­op the mys­te­ri­ous con­stel­la­tion of symp­toms, usu­al­ly di­ag­nosed many weeks af­ter the ini­tial ill­ness. But some ex­perts think a wave of long COVID is like­ly and say doc­tors need to be pre­pared for it.

With $1 bil­lion from Con­gress, the Na­tion­al In­sti­tutes of Health is fund­ing a vast ar­ray of re­search on the con­di­tion. And clin­ics de­vot­ed to study­ing and treat­ing it are pop­ping up around the world, af­fil­i­at­ed with places such as Stan­ford Uni­ver­si­ty in Cal­i­for­nia and Uni­ver­si­ty Col­lege Lon­don.

WHY DOES IT HAP­PEN?

Mo­men­tum is build­ing around a few key the­o­ries.

One is that the in­fec­tion or rem­nants of the virus per­sist past the ini­tial ill­ness, trig­ger­ing in­flam­ma­tion that leads to long COVID.

An­oth­er is that la­tent virus­es in the body, such as the Ep­stein-Barr virus that caus­es mononu­cle­o­sis, are re­ac­ti­vat­ed. A re­cent study in the jour­nal Cell point­ed to Ep­stein-Barr in the blood as one of four pos­si­ble risk fac­tors, which al­so in­clude pre-ex­ist­ing Type 2 di­a­betes and the lev­els of coro­n­avirus RNA and cer­tain an­ti­bod­ies in the blood. Those find­ings must be con­firmed with more re­search.

A third the­o­ry is that au­toim­mune re­spons­es de­vel­op af­ter acute COVID-19.

In a nor­mal im­mune re­sponse, vi­ral in­fec­tions ac­ti­vate an­ti­bod­ies that fight in­vad­ing virus pro­teins. But some­times in the af­ter­math, an­ti­bod­ies re­main revved up and mis­tak­en­ly at­tack nor­mal cells. That phe­nom­e­non is thought to play a role in au­toim­mune dis­eases such as lu­pus and mul­ti­ple scle­ro­sis.

Justy­na Fert-Bober and Dr. Su­san Cheng were among re­searchers at Cedars-Sinai Med­ical Cen­ter in Los An­ge­les who found that some peo­ple who have had COVID-19, in­clud­ing cas­es with­out symp­toms, have a va­ri­ety of these el­e­vat­ed “au­toan­ti­bod­ies” up to six months af­ter re­cov­er­ing. Some are the same ones found in peo­ple with au­toim­mune dis­eases.

An­oth­er pos­si­bil­i­ty is that tiny clots play a role in long COVID. Many COVID-19 pa­tients de­vel­op el­e­vat­ed lev­els of in­flam­ma­to­ry mol­e­cules that pro­mote ab­nor­mal clot­ting. That can lead to blood clots through­out the body that can cause strokes, heart at­tacks and dan­ger­ous block­ages in the legs and arms.

In her lab at Stel­len­bosch Uni­ver­si­ty in South Africa, sci­en­tist Re­sia Pre­to­rius has found mi­cro­clots in blood sam­ples from pa­tients with COVID-19 and in those who lat­er de­vel­oped long COVID. She al­so found el­e­vat­ed lev­els of pro­teins in blood plas­ma that pre­vent­ed the nor­mal break­down of these clots.

She be­lieves that these clot­ting ab­nor­mal­i­ties per­sist in many pa­tients af­ter an ini­tial coro­n­avirus in­fec­tion and that they re­duce oxy­gen dis­tri­b­u­tion to cells and tis­sue through­out the body, lead­ing to most if not all symp­toms that have been linked to long COVID.

IT CAN HIT NEAR­LY ANY­ONE

While there’s no firm list of symp­toms that de­fine the con­di­tion, the most com­mon in­clude fa­tigue, prob­lems with mem­o­ry and think­ing, loss of taste and smell, short­ness of breath, in­som­nia, anx­i­ety and de­pres­sion.

Some of these symp­toms may first ap­pear dur­ing an ini­tial in­fec­tion but linger or re­cur a month or more lat­er. Or new ones may de­vel­op, last­ing for weeks, months or over a year.

Be­cause so many of the symp­toms oc­cur with oth­er ill­ness­es, some sci­en­tists ques­tion whether the coro­n­avirus is al­ways the trig­ger. Re­searchers hope their work will pro­vide de­fin­i­tive an­swers.

Long COVID af­fects adults of all ages as well as chil­dren. Re­search shows it is more preva­lent among those who were hos­pi­tal­ized, but al­so strikes a sig­nif­i­cant por­tion who weren’t.

Re­tired flight at­ten­dant Jac­ki Gra­ham’s bout with COVID-19 at the be­gin­ning of the pan­dem­ic wasn’t bad enough to put her in the hos­pi­tal. But months lat­er, she ex­pe­ri­enced breath­less­ness and a rac­ing heart. She couldn’t taste or smell. Her blood pres­sure shot up.

In the fall of 2020, she be­came so fa­tigued that her morn­ing yo­ga would send her back to bed.

“I’m an ear­ly ris­er, so I’d get up and push my­self, but then I was done for the day,” said Gra­ham, 64, of Stu­dio City, Cal­i­for­nia. “Six months ago, I would have told you COVID has ru­ined my life.”

Hogan, the New York nurse, al­so wasn’t hos­pi­tal­ized with COVID-19 but has been de­bil­i­tat­ed since her di­ag­no­sis. Her hus­band, a dis­abled vet­er­an, and chil­dren ages 9, 13 and 15 fell ill soon af­ter and were sick with fever, stom­ach pains and weak­ness for about a month. Then all seemed to get a lit­tle bet­ter un­til new symp­toms ap­peared.

Hogan’s doc­tors think au­toim­mune ab­nor­mal­i­ties and a pre-ex­ist­ing con­nec­tive tis­sue dis­or­der that caus­es joint pain may have made her prone to de­vel­op­ing the con­di­tion.

PO­TEN­TIAL AN­SWERS

There are no treat­ments specif­i­cal­ly ap­proved for long COVID, though some pa­tients get re­lief from painkillers, drugs used for oth­er con­di­tions, and phys­i­cal ther­a­py. But more help may be on the hori­zon.

Im­muno­bi­ol­o­gist Akiko Iwasa­ki is study­ing the tan­ta­liz­ing pos­si­bil­i­ty that COVID-19 vac­ci­na­tion might re­duce long COVID symp­toms. Her team at Yale Uni­ver­si­ty is col­lab­o­rat­ing with a pa­tient group called Sur­vivor Corps on a study that in­volves vac­ci­nat­ing pre­vi­ous­ly un­vac­ci­nat­ed long COVID pa­tients as a pos­si­ble treat­ment.

Iwasa­ki, who is al­so an in­ves­ti­ga­tor with the Howard Hugh­es Med­ical In­sti­tute, which sup­ports The As­so­ci­at­ed Press’ Health and Sci­ence De­part­ment, said she is do­ing this study be­cause pa­tient groups have re­port­ed im­prove­ment in some peo­ple’s long COVID symp­toms af­ter they got their shots.

Study par­tic­i­pant Nan­cy Rose, 67, of Port Jef­fer­son, New York, said many of her symp­toms waned af­ter she got vac­ci­nat­ed, though she still has bouts of fa­tigue and mem­o­ry loss.

Two re­cent­ly re­leased stud­ies, one from the U.S. and one from Is­rael, of­fer pre­lim­i­nary ev­i­dence that be­ing vac­ci­nat­ed be­fore get­ting COVID-19 could help pre­vent the lin­ger­ing ill­ness or at least re­duce its sever­i­ty. Both were done be­fore omi­cron emerged.

Nei­ther has been pub­lished in a peer-re­viewed jour­nal, but out­side ex­perts say the re­sults are en­cour­ag­ing.

In the Is­raeli study, about two-thirds of par­tic­i­pants re­ceived one or two Pfiz­er shots; the oth­ers were un­vac­ci­nat­ed. Those who had re­ceived two shots were at least half as like­ly to re­port fa­tigue, headache, mus­cle weak­ness or pain and oth­er com­mon long COVID symp­toms as the un­vac­ci­nat­ed group.

UN­CER­TAIN FU­TURE

With few clear an­swers yet, the fu­ture is murky for pa­tients.

Many, like Gra­ham, see im­prove­ment over time. She sought help through a long COVID pro­gram at Cedars-Sinai, en­rolled in a study there in April 2021, and was vac­ci­nat­ed and boost­ed.

To­day, she said, her blood pres­sure is nor­mal, and her sense of smell and en­er­gy lev­el are get­ting clos­er to pre-COVID lev­els. Still, she wound up re­tir­ing ear­ly be­cause of her or­deal.

Hogan still strug­gles with symp­toms that in­clude ag­o­niz­ing nerve pain and “spaghet­ti legs,” or limbs that sud­den­ly be­come limp and un­able to bear weight, a con­di­tion that al­so af­fects her 13-year-old son.

Some sci­en­tists wor­ry that long COVID in cer­tain pa­tients might be­come a form of chron­ic fa­tigue syn­drome, a poor­ly un­der­stood, long-last­ing con­di­tion that has no cure or ap­proved treat­ment.

One thing’s for sure, some ex­perts say: Long COVID will have a huge ef­fect on in­di­vid­u­als, health care sys­tems and economies around the world, cost­ing many bil­lions of dol­lars.

Even with in­sur­ance, pa­tients can be out thou­sands of dol­lars at a time when they’re too sick to work. Gra­ham, for ex­am­ple, said she paid about $6,000 out of pock­et for things like scans, labs, doc­tor vis­its and chi­ro­prac­tic care.

Pre­to­rius, the sci­en­tist in South Africa, said there is re­al wor­ry things could get worse.

“So many peo­ple are los­ing their liveli­hoods, their homes. They can’t work any­more,” she said. “Long COVID will prob­a­bly have a more se­vere im­pact on our econ­o­my than acute COVID.”

 

Omicron variantOmicronLong covid


Related articles

Sponsored

Weather

PORT OF SPAIN WEATHER

Sponsored